Heterogeneity of treatment effect (HTE) refers to the nonrandom variation in the magnitude or direction of a treatment effect across levels of a covariate, as measured on a selected scale, against a clinical outcome. In randomized controlled trials (RCTs), HTE is typically examined through a subgroup analysis that contrasts effects in groups of patients defined "1 variable at a time" (for example, male vs. female or old vs. young). The authors of this statement present guidance on an alternative approach to HTE analysis, "predictive HTE analysis." The goal of predictive HTE analysis is to provide patient-centered estimates of outcome risks with versus without the intervention, taking into account all relevant patient attributes simultaneously. The PATH (Predictive Approaches to Treatment effect Heterogeneity) Statement was developed using a multidisciplinary technical expert panel, targeted literature reviews, simulations to characterize potential problems with predictive approaches, and a deliberative process engaging the expert panel. The authors distinguish 2 categories of predictive HTE approaches: a "riskmodeling" approach, wherein a multivariable model predicts the risk for an outcome and is applied to disaggregate patients within RCTs to define risk-based variation in benefit, and an "effect-modeling" approach, wherein a model is developed on RCT data by incorporating a term for treatment assignment and interactions between treatment and baseline covariates. Both approaches can be used to predict differential absolute treatment effects, the most relevant scale for clinical decision making. The authors developed 4 sets of guidance: criteria to determine when risk-modeling approaches are likely to identify clinically important HTE, methodological aspects of risk-modeling methods, considerations for translation to clinical practice, and considerations and caveats in the use of effect-modeling approaches. The PATH Statement, together with its explanation and elaboration document, may guide future analyses and reporting of RCTs. M edical treatment decisions by clinicians and patients are generally based-implicitly or explicitly-on predictions of outcomes under alternative treatment conditions. Under the paradigm of evidence-based medicine (EBM), the results of randomized controlled trials (RCTs), singly or aggregated in meta-analysis, are the primary evidence used to support these predictions.
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Popular approaches to EBM have encouraged the direct application of summary trial results to guide decision making for individuals, as though all patients meeting trial enrollment criteria are likely to similarly experience the benefits and harms of treatment. Yet, recognition has been growing that patients enrolled in trials typically differ in many ways that might be relevant; in particular, they can differ substantially in risk for the outcome and in the balance of benefits and harms of treatment. Thus, there is also growing recognition of the limitations of summary RCT results as tools for prediction in individualized clinical decision making, even among trial-eligible patients (1) (2) (3) .
Understanding how a treatment's effect can vary across patients (4 -10), a concept described as heterogeneity of treatment effect (HTE), is central to the research agenda for both personalized (or precision) medicine and comparative effectiveness research. We define HTE as nonrandom variation in the magnitude or direction of a treatment effect across levels of a covariate (that is, a patient attribute or set of attributes) against a clinical outcome. Because treatment effect can be measured on different scales (such as absolute risk difference or relative risk reduction), HTE is fundamentally a scale-dependent concept (that is, its presence or absence depends on the scale with which the effect is measured) (11) .
Extensive literature exists on conventional subgroup analyses, which serially divide the trial population into groups (for example, male vs. female or old vs. young) and examine contrasts in relative treatment effects (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . Although potentially useful for exploring hypotheses about factors that modify a treatment effect, these "1-variable-at-a-time" analyses have important limitations. Briefly, low statistical power, multiplicity, and weak prior theory on relative effect modifiers make subgroup analyses prone to both false-negative and false-positive results (23) (24) (25) . Such analyses also do not provide patient-centered estimates of treatment effects because patients have many attributes that simultaneously affect the outcome of interest and the benefits of treatment. The well-appreciated limitations of subgroup analysis have reinforced the reliance on summary trial results for clinical decision making and the false impression that harm-benefit tradeoffs are similar for all patients meeting trial enrollment criteria (3, 6) .
Predictive approaches to HTE analysis are designed to address some of these limitations. The goal of predictive HTE analysis is to provide individualized predictions of treatment effect that are defined by the difference between expected potential outcomes of interest in a particular patient with one intervention versus an alternative and that take into account multiple relevant characteristics simultaneously (7, 26) . Although guidance is expanding regarding optimal approaches to prediction modeling ( The PATH (Predictive Approaches to Treatment effect Heterogeneity) Statement outlines principles, criteria, and key considerations for applying predictive HTE approaches to clinical trials to provide patient-centered evidence in support of decision making. The primary focus of this effort is the identification of clinically important HTE-that is, variation in the risk difference across patient subgroups that may be sufficient to span clinically defined decision thresholds (6, 9, 26) . In this article, we summarize criteria to determine when riskmodeling approaches are likely to identify clinically important HTE, review critical methodological aspects of these methods, and identify considerations and caveats for translation to clinical practice. We focus on modeling strategies that use regression analysis but acknowledge a wide set of other approaches (such as tree methods and machine learning). The PATH Statement is intended to be used in conjunction with the explanation and elaboration document (31) , which expands on the intent of each recommendation; describes the rationale for each; and discusses related analytic considerations, caveats, and reservations.
PREDICTIVE HTE APPROACHES: RISK MODELING VERSUS EFFECT MODELING
The main goal of predictive HTE analysis is to develop models that can predict which of 2 or more treatments will be better for a particular patient. We distinguish predictive HTE analyses from HTE analyses with other goals, such as those more focused on causal interaction, which include both exploratory (hypothesisgenerating) and confirmatory (hypothesis-testing) subgroup analyses. The explanation and elaboration document (31) more fully discusses differing concepts of "interaction" and HTE and contains a glossary of key definitions; a recent narrative review (26) , developed as background to the PATH Statement, also provides important context.
Predictive HTE analysis generally comprises 2 steps: variable and model selection to define the reference class (or subgrouping) scheme, and effect estimation across different strata of that scheme. Following a previous review (26) , we distinguish 2 distinct approaches to predic-tive HTE analysis (26) . The first is "risk modeling," in which a multivariable model that predicts risk for an outcome is applied to stratify patients within trials to examine riskbased variation in treatment effects. In the second approach, "effect modeling," a model is developed on RCT data with inclusion of a treatment assignment variable and potential inclusion of treatment interaction terms. Both approaches can be used to predict differential absolute treatment effects-that is, a difference in outcome risks under 2 alternative treatments. We describe each briefly in the following sections.
Risk Modeling
Risk modeling relies on the mathematical dependency of treatment effect on the control event rate ( Table 1) , an observable proxy for outcome risk. When risk is described through a combination of factors (32) , the control event rate will typically vary considerably across the trial population. The absolute risk difference-the most clinically important effect measure-will generally vary across risk strata even if the relative risk is the same (32) . When a trial population has substantial variation in outcome risk, important differences often exist in harm-benefit tradeoffs ( Figure 1 ) (3, 26) . For this reason, risk models can be useful in identifying "clinically important HTE," which is evaluated on the absolute risk difference scale.
A risk-modeling approach is typically done in 2 steps. First, a multivariable regression model that predicts risk for an outcome (usually the primary study outcome) is identified from external sources (an "external model") or developed directly on the trial population without a term for treatment assignment (an "internal model") (equation 1 in Table 2 ). Next, this model is applied to stratify patients within trials and examine risk-based variation in treatment effects. The essential feature that distinguishes a riskmodeling approach from effect modeling (described in the next section) is that the reference class (or subgrouping) scheme is defined by a model developed "blinded" to treatment assignment. Figure 1 shows a schematized and an actual example of the risk-modeling approach to trial analysis, in which both relative effects and absolute effects vary by baseline risk across the trial population. In the examples shown, patients are divided using quantiles (such as quartiles) of risk, and treatment effect is estimated in risk groups for reporting purposes. Figure 2 of the explanation and elaboration document (31) shows an alternative form of presentation in which outcomes are shown by predicted risk itself (as a continuous variable), rather than grouped by risk quantiles. Variation in the treatment effect is tested statistically on the relative scale, 
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The PATH Statement Conventional "1-variable-at-a-time" subgroup analyses are typically inadequate to disaggregate patients into groups that are sufficiently heterogeneous for risk, so benefit-harm tradeoffs can misleadingly seem to be consistent across the trial population. Although this figure shows idealized relationships between risk and treatment effects, these relationships will be sensitive to how risk is described (i.e., what variables are in the risk model). Baseline risk has a logit-normal distribution, with μ = Ϫ3 and = 1 (the log odds are normally distributed). Adapted from reference 3. Q1 = first risk quarter (lowest); Q2 = second risk quarter; Q3 = third risk quarter; Q4 = fourth risk quarter (highest). B. Stratified results of RITA-3 (Randomized Intervention Trial of unstable Angina 3) (33). The RITA-3 trial (n = 1810) tested early intervention vs. conservative management of non-ST-segment elevation acute coronary syndrome. Results for the outcome of death or nonfatal myocardial infarction at 5 y are shown, stratified into equal-sized risk quarters using an internally derived risk model; the highest-risk quarter is substratified into halves (groups 4a and 4b). Event rates with 95% CIs (top), odds ratios (middle), and risk differences (bottom) are shown. The risk model comprises the following easily obtainable clinical characteristics: age, sex, diabetes, prior myocardial infarction, smoking status, heart rate, STsegment depression, angina severity, left bundle branch block, and treatment strategy. As in the schematic diagram to the left, the average treatment effect seen in the summary results (horizontal dashed line in middle and bottom panels) closely reflects the effect in patients in risk group 3, whereas half of patients (risk groups 1 and 2) receive no treatment benefit from early intervention. Absolute benefit (bottom) in the primary outcome was very pronounced in the eighth of patients at highest risk (risk group 4b). A statistically significant risk-bytreatment interaction can be seen when results are expressed in the odds ratio scale (middle) (the interaction P value is from a likelihood ratio test for adding an interaction between the linear predictor of risk and treatment assignment). Such a pattern can emerge if early intervention is associated with some procedure-related risks that are evenly distributed over all risk groups, eroding benefit in low-risk but not high-risk patients, as illustrated schematically in the left panel.
The PATH Statement RESEARCH AND REPORTING METHODS here using an interaction between the linear predictor of risk and treatment (equation 2 in Table 2 ). Results are also presented on the scale of absolute risk difference. In RITA-3 (Randomized Intervention Trial of unstable Angina 3) ( Figure 1, right) , which compared an invasive versus a noninvasive approach for acute coronary syndrome, the eighth of patients at highest risk had an outcome rate approximately 8-fold higher than patients in the lowest-risk quarter. In these high-risk patients, the benefits of therapy outweigh the harms, whereas low-risk patients did not benefit.
For translation to clinical practice, modeling treatment effects across the full risk spectrum (that is, as a continuous variable) can provide more individualized predictions of treatment effect. When relative effects seem to be constant across risk strata, a model with a constant treatment effect may suffice (equation 3 in Table 2 ). Including a treatment interaction with the linear predictor of risk permits the relative treatment effect to vary linearly across levels of risk (equation 2 in Table 2 ). Nonlinear interactions between risk and treatment can also be considered. Of note, the exact relationship between risk and treatment effect will depend on the variables included in the risk model.
Effect Modeling
In the second approach, effect modeling, a regression model is developed directly on RCT data with inclusion of risk predictors and a treatment assignment variable and may include treatment interaction terms (equation 4 in Table 2 ). Because these models include interaction terms between treatment and baseline covariates, they are vulnerable to some of the same problems that undermine conventional subgroup analysis (low power, multiplicity, and limited prior knowledge about important effect modifiers) (26) . On rare occasions, highly credible treatment effect interactions exist and should be taken into account when predicting effects in individuals; however, data-driven effect models are prone to bias due to false or exaggerated interaction effects (31, 34) , particularly when tests of statistical significance are used to select interaction terms (34, 35) . Methods to address these concerns include use of "penalization" to shrink model coefficients to avoid overfitting (36, 37) and use of a 2-step process of first developing the model on randomized data to define the subgrouping (or reference class) scheme and then using a second data set to estimate the treatment effect (38, 39) . Practical experience with these data-driven methods is limited, and a robust literature comparing the rapidly emerging approaches is lacking thus far (40 -45) . Thus, the technical expert panel elected to limit methodological recommendations to those circumstances where specific, highly credible treatment effect interactions have been identified. Although we recognize data-driven effect modeling as a promising area of research, we limit our comments to underscoring caveats and various concerns. A recent review (46) discusses emerging, data-driven approaches to effect modeling.
DEVELOPING THE PATH STATEMENT
To develop the PATH Statement criteria and considerations, we adopted an approach that combined expert opinion, review of the literature, and simulation studies (detailed elsewhere [34] ).
The PATH Technical Expert Panel
We assembled a panel of 16 experts who would represent various perspectives on these analyses. The PATH technical expert panel comprised experts in HTE, prediction modeling, clinical trials, and guideline development and a patient advocate (Appendix Table 1 , available at Annals.org, provides the full roster).
Literature Review
The cochairs of the technical expert panel (D.M.K. and E.S.) led a literature review of important articles related to the conduct of predictive HTE analyses (26) . We developed a library of relevant methodological and applied articles on the topic of predictive HTE analysis in randomized trials, as well as articles related to interaction testing and subgroup analysis. Additional articles were solicited from the panelists and made available to them in an online library. In addition, an evidence review committee (chaired by J.B.W.) did a systematic scoping review (detailed elsewhere [47] ) to Table 2 
. Equations Corresponding to Risk-Modeling and Effect-Modeling Approaches

Risk modeling
A multivariable regression model f that predicts the risk for an outcome based on risk predictors x i is identified or developed:
Variation in the treatment effect across risk can be tested statistically on the relative scale through the interaction between a linear predictor of risk (lp = ␤ 1 × x 1 + . . . + ␤ p × x p ) and treatment assignment tx:
Including a treatment interaction with the linear predictor of risk permits the relative treatment effect to vary linearly across levels of risk (and permits testing of the statistical significance of this interaction effect, ␦ lp ). When relative effects across risk strata seem constant, a model with a constant treatment effect may suffice:
where the parameter ␤ tx represents a constant risk reduction on the log hazard or log odds scale for treated (tx = 1) versus control (tx = 0) patients.
Effect modeling
A regression model f is developed on RCT data with inclusion of risk predictors x i , a treatment assignment variable tx, and potential treatment interaction terms (x i × tx):
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The PATH Statement identify methodological studies of predictive HTE analysis in RCTs that use regression methods. The goal was to generate an annotated bibliography to guide and support the development of the PATH Statement and to inform future work.
Consensus-Building Process
We used a modified Delphi process (48) to build consensus among panelists to address the main objectives of the PATH Statement. ThinkTank, a cloud-based collaborative platform, facilitated consensus building.
From February to June 2018, the PATH Statement cochairs convened five 2-hour Webinars and one 4-hour in-person meeting to develop consensus. The first meeting was designed to define scope, timeline, and expectations for the PATH Statement. Two additional Webinars were convened in April and July 2019 to consider alterations to recommendations in response to reviewer comments (Appendix Table 2 , available at Annals.org).
During each Webinar, criteria were scored on a 5-point scale for agreement, importance, and feasibility of assessment. A trained facilitator (J.K.P.) attended Webinars to moderate discussion, structure verbal and electronic communication, and review agreement on criteria. Each vote was recorded, and panelists then had an open discussion centered on areas of disagreement. Items with an SD greater than 1 or mean ratings less than 4 (on 5-point scales) were prioritized for discussion as low-consensus criteria. After discussion, some criteria were deleted, consolidated, or revised, and panelists had the opportunity to revise their judgments with a revote before the next meeting. The criteria for consensus agreement were mean ratings of 4 or more and an SD of 1 or less on the 5-point agreement scale after rounds of discussion and rerating. In the week after a PATH Statement meeting, items reaching consensus and those with limited agreement were distributed to members via e-mail for refinement. Appendix Tables 3 to 5 (available at Annals.org) provide the results of the final votes on criteria, considerations, and caveats.
Role of the Funding Source
The Patient-Centered Outcomes Research Institute had no role in study design, data collection, analysis, manuscript preparation, or the decision to submit the manuscript for publication.
THE PATH STATEMENT
The PATH Statement comprises 4 sets of guidance (Figures 2 to 5) on the conduct of predictive HTE analyses and is briefly summarized in this section; the explanation and elaboration document (31) provides important clarifying details.
First, we developed consensus criteria to define the decision-making, data, design, and analytic context in which the application of risk-modeling approaches is likely to yield clinically informative results ( Figure 2) . The technical expert panel agreed that risk-modeling approaches should generally be applied when an overall treatment effect exists and considered cautiously when it does not, given the potential for false-positive findings. The criteria emphasized conditions where substantial heterogeneity in outcome risk is probable and where this risk heterogeneity is likely to induce important heterogeneity in benefit-harm tradeoffs. This will occur when substantial and identifiable heterogeneity in outcome risk in the trial population is anticipated (that is, a broad case mix) and when treatments are associated with a nontrivial amount of serious harm or burden. Figure 1 (right) shows a clinical example where outcome rates vary dramatically from the highrisk to the low-risk group and a small amount of treatment-related harm may be sufficient to erode much (or all) of the benefit in low-risk patients. Pragmatic and data-related criteria emphasized the availability of several large, randomized, well-conducted clinical trials of contemporary interventions for individual patient meta-analysis and prioritized cases where the variables needed for prediction are routinely available in clinical care. Two additional criteria did not reach consensus (Appendix Table 3 ). Prior work sug- The PATH Statement RESEARCH AND REPORTING METHODS gests that risk modeling might be more informative when the incidence of the outcome is lower (which can lead to more heterogeneity and skewness of risk [32] ), but the expert panel was divided on the importance of this criterion.
In Figure 3 , we present guidance on best methodological practices to conduct risk modeling to identify HTE, including overarching guidance and that on identifying or developing a risk model, applying the model, and reporting results. This guidance emphasizes the application of a high-quality, externally developed risk model to stratify trial results. Alternatively, when a compatible external model is not available, an internal (or endogenous) risk model that was developed on the entire trial population without a term for treatment assignment (49, 50) can be applied. In either case, the analysis plan should be fully specified before the data are examined. Internal models developed only on the control group (to predict baseline risk, if untreated) are prone to inducing or exaggerating interactions between treatment and risk because of differential fit between the 2 treatment groups. Even slight overfitting on the control group could bias treatment effect estimates across levels of risk (34, 50, 51) . Our guidance on reporting the results of risk-stratified analyses underscores the importance of reporting serious treatmentrelated harms within each stratum to support evaluation of stratum-specific tradeoffs between benefit and harm and the appropriate conduct of statistical hypothesis testing.
Translation of findings from predictive HTE analyses into clinical practice is a complex topic that includes many issues, such as human factors, aspects of model implementation, coping with missing patient characteristics in real-world clinical practice, risk communication, and model transportability. Although a detailed discussion of these challenges is beyond the scope of this project, a set of caveats and considerations for the translation of predictive HTE analyses into clinical practice was developed and is presented in Figure 4 . Results should be reported on both absolute and relative scales, but the importance of interpreting treatment effects on the clinically relevant scale (absolute risk difference rather than relative effects) was emphasized (52), as was the importance of external validation and calibration of the risk model used for trial stratification to the target population of interest. 
Clinical interpretation of HTE should stress differences in the absolute treatment effects across risk groups:
The statistical significance of effect modification on the relative scale should not be conflated with the clinical significance of absolute treatment effect estimates.
External validation and calibration of risk prediction is important for translation of risk-specific treatment effects into clinical practice. 3. Clinical implementation may be supported by translating multivariable risk-based subgroup analysis into models yielding continuous treatment effect predictions to avoid artifactual discontinuities in estimation at the quantile boundary of an outcome risk group.
HTE = heterogeneous treatment effects.
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When highly credible relative effect modifiers have been identified, they should be incorporated into prediction models using multiplicative treatment-by-covariate interaction terms ( Figure 5 ). Credibility should be evaluated using rigorous multidimensional criteria (such as those described by the Instrument for assessing the Credibility of Effect Modification ANalyses [ICEMAN tool] [53] and including the strength of a priori direct or indirect evidence) and should not rely solely on statistical criteria (such as P value thresholds). We anticipate that highly credible interactions will generally be rare when randomized clinical trials of conventional size are used. In the absence of such interactions, the technical expert panel advised caution in the use of data-driven effect models for the following reasons: Practical experience with datadriven effect modeling (that is, where statistical approaches are used to explore and select out effect modifiers on the relative scale) is limited, these flexible approaches are vulnerable to false discoveries of promising subgroup effects, the variety of competing approaches is growing, and robust literature comparing the different approaches is lacking. Thus, we restricted our recommendations to a set of considerations and caveats for these more "aggressive" modeling techniques (that is, those using more degrees of freedom for estimation of the differential treatment effect). These statements emphasized the need to address the potential for overfitting that can lead to signals of treatment benefit and harm even for interventions that are completely ineffective and innocuous (34) . This is a particular problem for modeling RCT data, where power for statistical interaction of relative effects is generally limited, as are opportunities for external validation.
THE PATH EXPLANATION AND ELABORATION DOCUMENT
A supporting explanation and elaboration document (31) clarifies and expands on the motivation and reservations regarding items in the PATH Statement. The document explains each recommendation in more detail and provides (where relevant) clinical applications of methods, supporting methodological evidence, and caveats or limitations. It also describes spe-cial considerations for evaluating models that predict benefit. The literature reviews done as part of this project were used to justify the rationale for guidance statements or criteria. The explanation and elaboration document was developed after the PATH Statement criteria reached final consensus, with input from panelists via several face-to-face meetings, teleconferences, and iterations among the authors. Additional revisions were made after the document was shared with the whole PATH Statement group before final approval.
DISCUSSION
The field of EBM has historically emphasized the results of randomized trials (and their meta-analysis) as the best evidence for clinical decision making. However, patient attributes may influence the probability of the outcome of interest and the benefits of treatment. The goal of personalized EBM can be conceived as the identification of an optimal subgrouping (or reference class) scheme, based on all relevant patient characteristics, that yields more individualized estimates of treatment effects for each patient than the average trial result, thus improving overall outcomes (26) . In fact, the most common definition of EBM from more than 20 years ago anticipates the need to make decisions for individual patients (54) . Thus, the goal of personalization has been at the core of EBM since its inception, although the limitations of summary trial results in supporting this goal have been inconsistently recognized.
The PATH Statement was developed to address this gap. Although the statement and its explanation and elaboration document are supported by a substantial and growing body of evidence, and although they build on prior efforts to offer methodological guidance on predictive approaches to HTE (5, 6) , this represents the first such guidance developed by a diverse set of experts and stakeholders with differing views and perspectives that involved an iterative process of discussion, feedback, and revision. The guidance thus aims to assist a diverse set of relevant stakeholders, including researchers, regulators, industry professionals, and guideline-writing bodies.
We focused on risk modeling, and we acknowledge that the more comprehensive and flexible effect- 1-variable-at-a-time null hypothesis testing or stepwise selection (e.g., backward selection, forward selection) strategies to select single-variable relative effect modifiers. 3. Avoid the use of regression methods that do not take into account model complexity when estimating coefficients (e.g., "conventional" unpenalized maximum-likelihood regression) when 1 or more treatment-by-covariate interaction terms are included in a treatment effect model. 4. Avoid evaluating models that predict treatment benefit using only conventional metrics for outcome risk prediction (e.g., based on discrimination and calibration of outcome risk prediction).
When highly credible relative effect modifiers have been identified, they should be incorporated into prediction models using multiplicative treatment-by-covariate interaction terms. A. Credibility should be evaluated using rigorous multidimensional criteria and should not rely solely on statistical criteria (such as P value thresholds). 2. Avoid
HTE = heterogeneous treatment effects.
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Annals.org Annals of Internal Medicine modeling approach (incorporating treatment interaction terms with individual effect modifiers) holds promise-particularly in data sets that are substantially larger than those from conventional RCTs. Capturing the benefits of effect modeling while avoiding the potential harms of overfitting is an area of intense research interest (36, 38, 39, 49, (55) (56) (57) (58) (59) (60) (61) and a central challenge for future study. Nevertheless, considerable evidence suggests that risk-modeling approaches can frequently provide clinically important insights-beyond those provided by overall trial results-that can directly improve decision making (33, 40 -45, 62, 63) . The PATH Statement focuses on regression-based prediction in randomized trials. A broad and evolving tool kit exists for data-driven approaches to predicting patient benefit, including machine-learning techniques (46, 64) . As experience grows, we anticipate stronger methodological and evidentiary guidance that will allow a fuller understanding of the appropriate contexts and the advantages and limitations of these more flexible modeling methods. In addition, although observational studies seem to offer many important advantages over conventional RCTs for more refined analyses (that is, enhanced statistical power and patient heterogeneity), when these data may be sufficiently debiased for reliable determination of treatment effects or HTE is not well understood (9, 65) . Our PATH Statement identified these issues as high research priorities.
Predictive HTE methods can often be usefully applied to individual large clinical trials (33, 40 -45, 62, 63) . However, the PATH Statement authors recognize that fully realizing the goals of improved evidence personalization also depends on increased collaborative efforts to create pooled data substrates that are more conducive to these analyses than individual trials, and on the implementation of innovative trial designs-including those sampling larger and broader populations-that may enrich the heterogeneity of clinical trial populations. The PATH Statement is intended to encourage and motivate these innovations.
We also need research to better integrate clinical prediction into practice (66, 67) ; to understand how to individualize clinical practice guidelines; to establish or extend reporting guidelines (29) ; to establish new models of data ownership to facilitate data pooling (68); and to reengineer the clinical research infrastructure to support substantially larger, clinically integrated trials that are sufficiently powered to determine HTE (69) . Many recent and ongoing organizational and technical advances should enable this evolution (68, 70 -73) . The collaborative work in the field of genetic epidemiology (74) may serve as a useful model for HTE prediction if we are to optimally address many of the challenges to individualizing evidence.
The PATH technical expert panel recognizes the inherent difficulties and fundamental limitations of using group data to estimate treatment effects in individuals (9) . In particular, individual treatment effects are inherently unobservable (in parallel-group studies), and individual patients do not have uniquely identifiable risks (9, 26, (75) (76) (77) . Nevertheless, clinicians are required to make decisions 1 patient at a time. The PATH Statement provides guidance for analytic approaches that seek to advance our ability to provide more patientcentered estimates of treatment effects. We present it as an important formative step in a long-term research effort to better personalize evidence from comparative effectiveness data. 
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